Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 3/20 | 0.31 |
| ▸ | ACE | P12821 | 3/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969187 | 1.00 | KMT2A (0.33) | KMT2AMEN1BRD4TDP1ALOX15 | |
| SCHEMBL1219564 | 1.00 | KMT2A (0.33) | KMT2AMEN1BRD4TDP1ALOX15 | |
| SCHEMBL4972064 | 1.00 | KMT2A (0.33) | KMT2AMEN1BRD4TDP1ALOX15 | |
| SCHEMBL4972145 | 0.88 | EGFR (0.37) | KMT2AMEN1LMNAMMEACE | |
| SCHEMBL10359001 | 0.87 | POLB (0.38) | KMT2AMEN1TDP1ALOX15HSD17B10 | |
| SCHEMBL10359000 | 0.87 | POLB (0.38) | KMT2AMEN1TDP1ALOX15HSD17B10 | |
| SCHEMBL1201887 | 0.87 | BRD4 (0.43) | KMT2AMEN1BRD4ALOX15HSD17B10 | |
| SCHEMBL10359065 | 0.87 | BRD4 (0.34) | KMT2AMEN1BRD4ALOX15HSD17B10 | |
| SCHEMBL4970660 | 0.86 | EGFR (0.36) | KMT2AMEN1TDP1NOTUMEGFR | |
| SCHEMBL10359099 | 0.86 | MEN1 (0.32) | KMT2AMEN1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120114457-A | Aldose reductase inhibitors for the treatment of phosphomannomutase 2 deficiency | 应用治疗公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119971038-A | Compositions and methods for treating galactosylation | 应用治疗公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250140406-A1 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | INSIGHT MOLECULAR DIAGNOSTICS INC. | 2025-05-01 | — | — | US | disclosed |
| CN-114667139-B | Aldose reductase inhibitors for the treatment of phosphomannomutase 2 deficiency | 应用治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119633117-A | Compositions and methods for treating galactosylation | 应用治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-111065392-B | Compositions and methods for treating galactosylation | 应用治疗公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4417260-A2 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | Applied Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240238288-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | BARCLAYS BANK PLC (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230121312-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | Applied Therapeutics, Inc. | 2023-04-20 | — | — | US | disclosed |
| US-11590131-B2 | Compositions and methods for treating galactosemia | Applied Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230058134-A1 | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY | BARCLAYS BANK PLC (GB) | 2023-02-23 | — | — | US | disclosed |
| EP-4135674-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | Applied Therapeutics Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-4125909-A1 | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY | Applied Therapeutics Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4041219-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | Applied Therapeutics, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220226323-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | BARCLAYS BANK PLC (GB) | 2022-07-21 | — | — | US | disclosed |
| CN-114667139-A | Aldose reductase inhibitors for the treatment of phosphomannomutase 2 deficiency | 应用治疗公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220071880-A1 | METHODS FOR TREATING CUTANEOUS AGING | Applied Therapeutics, Inc. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590131-B2 | Compositions and methods for treating galactosemia | GLA, ALDOA, GALC | KMT2A 2585/4885MEN1 3693/4885BRD4 3699/4885 |
| US-20240238288-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | SORD, SDHA, SDHB | KMT2A 2370/4885MEN1 2784/4885BRD4 4630/4885 |
| US-20230121312-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | SORD, SDHA, SDHB | KMT2A 2370/4885MEN1 2784/4885BRD4 4630/4885 |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | KMT2A 2591/4885MEN1 3081/4885BRD4 3149/4885 |
| US-20220226323-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | PMM2, PGM2, ALDOA | KMT2A 1292/4885MEN1 1744/4885BRD4 4626/4885 |
| US-20220071880-A1 | METHODS FOR TREATING CUTANEOUS AGING | GLA, ADH1B, ALDH2 | KMT2A 3379/4885MEN1 4840/4885BRD4 3466/4885 |
| US-20230058134-A1 | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY | ALDOA, AKR1B1, ACE | KMT2A 2858/4885MEN1 4726/4885BRD4 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.